EUVIMEDEUVIMED entdecken
Crossref

Clinical features and risk factors of flare in anti-synthetase syndrome

Anna Hasegawa, Kazuhiro Kurasawa, Ryota Koike, Rika Sato, Azusa Kikuchi, Sara Komatsu, Yusuke Sakaue, Yuki Aizawa, Aya Shimizu, Yuhi Yoshida, Tomoka Hiyama, Tomoyuki Miyao und 5 weitere

Clinical Rheumatology · 2025-06 · 44 (6) · 2431-2438

DOI: 10.1007/s10067-025-07398-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Rheumatology, online erschienen am 09.04.2025. Verfasst von Anna Hasegawa und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Dokkyo Medical University, Mibu, Japan. Hauptthemen laut MEDLINE: Myositis, Amino Acyl-tRNA Synthetases, Lung Diseases, Interstitial. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: To clarify clinical features and risk factors of flares in anti-synthetase syndrome (ASS). METHODS: We retrospectively identified consecutive patients with ASS by reviewing medical records. Clinical, laboratory, and imaging data were obtained. Patients were considered to have a flare when treatment was intensified for myositis and/or ILD with an increased dose of glucocorticoid (GC) and/or addition of a new immunosuppressant (IS). RESULTS: A total of 51 subjects were included. All 51 patients had ILD, 38 patients had myositis, and 39 patients had skin rash. Anti-aminoacyl-tRNA synthetase (ARS) antibody subtypes were anti-Jo-1 in 23 (45%), anti-EJ in 13 (25%), anti-PL-7 in 8 (16%), and anti-PL-12 in 7 (14%). As initial therapy, half of the patients were treated with GCs alone, while the rest were treated with a combination of GCs and ISs during observation. Flares occurred in 30 (58%) mostly when the prednisolone dose was tapered to 11 mg/day. Patients with anti-EJ or anti-Jo-1 frequently flared. The use of calcineurin inhibitors (CNIs) was significantly associated with less flares of myositis but not with those of ILD. In multivariate analyses, anti-ARS subtype and Gottron's sign were identified as independent risk factors for overall flare. CONCLUSION: The majority of ASS patients experienced a flare, which frequently occurred when the GC dose was tapered to 11 mg of prednisolone. The presence of anti-EJ/Jo-1 antibody and Gottron's sign were identified as independent risk factors for flare. In addition, the use of CNIs tended to associate with less flares of myositis. Key Points • The majority of patients with anti-synthetase syndrome experience a flare when glucocorticoids are tapered close to 10 mg of prednisolone. • The presence of anti-EJ/Jo-1 antibody and Gottron's sign are risk factors for flares in patients with anti-synthetase syndrome. • The use of calcineurin inhibitors may prevent flares of myositis in patients with anti-synthetase syndrome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MyositisAmino Acyl-tRNA SynthetasesLung Diseases, InterstitialHumansMaleFemaleMiddle AgedRetrospective StudiesRisk FactorsGlucocorticoidsAdultAgedImmunosuppressive AgentsPrednisoloneCalcineurin InhibitorsAntibodies, Antinuclear

Stichwörter der Autor:innen

Anti-aminoacyl-tRNA synthetase antibodyAnti-synthetase syndromeFlareInterstitial lung diseaseMyositis

Substanzen

GlucocorticoidsImmunosuppressive AgentsPrednisoloneAmino Acyl-tRNA SynthetasesCalcineurin InhibitorsAntibodies, Antinuclear

Autor:innen und Institutionen

  • Department of Rheumatology, Dokkyo Medical University, Mibu, Japan.
  • Department of Rheumatology, Dokkyo Medical University, Mibu, Japan. k-ikeda847@dokkyomed.ac.jp.

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Hasegawa, A., Kurasawa, K., Koike, R., Sato, R., Kikuchi, A., Komatsu, S., Sakaue, Y., Aizawa, Y., Shimizu, A., Yoshida, Y., Hiyama, T., Miyao, T., Tanaka, A., Arai, S., Maezawa, R., Arima, M., & Ikeda, K. (2025). Clinical features and risk factors of flare in anti-synthetase syndrome. Clinical Rheumatology, 44(6), 2431-2438. https://doi.org/10.1007/s10067-025-07398-9

Vancouver

Hasegawa A, Kurasawa K, Koike R, Sato R, Kikuchi A, Komatsu S, et al. Clinical features and risk factors of flare in anti-synthetase syndrome. Clinical Rheumatology. 2025;44(6):2431-2438. doi:10.1007/s10067-025-07398-9

BibTeX
@article{Hasegawa2025,
  author = {Hasegawa, Anna and Kurasawa, Kazuhiro and Koike, Ryota and Sato, Rika and Kikuchi, Azusa and Komatsu, Sara and Sakaue, Yusuke and Aizawa, Yuki and Shimizu, Aya and Yoshida, Yuhi and Hiyama, Tomoka and Miyao, Tomoyuki and Tanaka, Ayae and Arai, Satoko and Maezawa, Reika and Arima, Masafumi and Ikeda, Kei},
  title = {Clinical features and risk factors of flare in anti-synthetase syndrome},
  journal = {Clinical Rheumatology},
  year = {2025},
  volume = {44},
  number = {6},
  pages = {2431--2438},
  doi = {10.1007/s10067-025-07398-9}
}
Kostenlos starten →